Follow-up of vascular-targeted photodynamic therapy in a real-world setting.
Focal therapy
Hemiablation
Long-term follow-up
Prostate cancer
VTP
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
20 Jan 2024
20 Jan 2024
Historique:
received:
31
07
2023
accepted:
30
10
2023
medline:
20
1
2024
pubmed:
20
1
2024
entrez:
20
1
2024
Statut:
epublish
Résumé
Vascular-targeted photodynamic therapy (VTP) is an approved treatment option for unilateral low-risk prostate cancer (PCa). Patients with unilateral low- or intermediate-risk PCa undergoing hemiablation by VTP were evaluated in a real-world setting. Oncological outcome after VTP was measured by MRI-based re-biopsy at 12 and 24 months. Functional outcome after 1 year was investigated by IIEF-5 and IPSS questionnaires. Progression was defined as the evidence3 of ISUP ≥ 2 PCa. At any control biopsy (n = 46) after VTP, only 37% of patients showed no evidence of PCa. Recurrence-free survival was 20 months (95% CI 4.9-45.5) and progression-free survival was 38.5 months (95% CI 33.5-43.6 months). In-field and out-field recurrent PCa occurs in 37% (55% ISUP ≥ 2 PCa) and 35% (56% ISUP ≥ 2 PCa). Seventy-nine percent of patients preserved erectile function, respectively. Ten percent of patients presented long-term bladder outlet obstruction. None of the patients presented incontinence. Due to the high-recurrence in- and out-field recurrence rate in a mainly low-risk prostate cancer cohort, VTP has to be regarded critically as a therapy option in these patients. Pre-interventional diagnostic evaluation is the main issue before focal therapy to reduce the risk of tumor recurrence and progression.
Identifiants
pubmed: 38244089
doi: 10.1007/s00345-023-04738-9
pii: 10.1007/s00345-023-04738-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
55Informations de copyright
© 2024. The Author(s).
Références
Bates AS, Ayers J, Kostakopoulos N, Lumsden T, Schoots IG, Willemse PM et al (2021) A systematic review of focal ablative therapy for clinically localised prostate cancer in comparison with standard management options: limitations of the available evidence and recommendations for clinical practice and further research. Eur Urol Oncol 4(3):405–423
doi: 10.1016/j.euo.2020.12.008
pubmed: 33423943
Marshall S, Taneja S (2015) Focal therapy for prostate cancer: the current status. Prostate Int 3(2):35–41
doi: 10.1016/j.prnil.2015.03.007
pubmed: 26157765
pmcid: 4494637
van der Poel HG, van den Bergh RCN, Briers E, Cornford P, Govorov A, Henry AM et al (2018) Focal therapy in primary localised prostate cancer: the European association of urology position in 2018. Eur Urol 74(1):84–91
doi: 10.1016/j.eururo.2018.01.001
pubmed: 29373215
Ahdoot M, Wilbur AR, Reese SE, Lebastchi AH, Mehralivand S, Gomella PT et al (2020) MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis. N Engl J Med 382(10):917–928
doi: 10.1056/NEJMoa1910038
pubmed: 32130814
pmcid: 7323919
Johnson DC, Raman SS, Mirak SA, Kwan L, Bajgiran AM, Hsu W et al (2019) Detection of individual prostate cancer foci via multiparametric magnetic resonance imaging. Eur Urol 75(5):712–720
doi: 10.1016/j.eururo.2018.11.031
pubmed: 30509763
Hopstaken JS, Bomers JGR, Sedelaar MJP, Valerio M, Futterer JJ, Rovers MM (2022) An updated systematic review on focal therapy in localized prostate cancer: what has changed over the past 5 years? Eur Urol 81(1):5–33
doi: 10.1016/j.eururo.2021.08.005
pubmed: 34489140
Flegar L, Buerk B, Proschmann R, Propping S, Groeben C, Baunacke M et al (2022) Vascular-targeted photodynamic therapy in unilateral low-risk prostate cancer in germany: 2-year single-centre experience in a real-world setting compared with radical prostatectomy. Eur Urol Focus 8(1):121–127
doi: 10.1016/j.euf.2021.01.018
pubmed: 33602642
Borkowetz A, Blana A, Bohmer D, Cash H, Ehrmann U, Franiel T et al (2022) German S3 evidence-based guidelines on focal therapy in localized prostate cancer: the first evidence-based guidelines on focal therapy. Urol Int 106(5):431–439
doi: 10.1159/000521882
pubmed: 35144260
Azzouzi AR, Vincendeau S, Barret E, Cicco A, Kleinclauss F, van der Poel HG et al (2017) Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. Lancet Oncol 18(2):181–191
doi: 10.1016/S1470-2045(16)30661-1
pubmed: 28007457
Gill IS, Azzouzi AR, Emberton M, Coleman JA, Coeytaux E, Scherz A et al (2018) Randomized trial of partial gland ablation with vascular targeted phototherapy versus active surveillance for low risk prostate cancer: extended followup and analyses of effectiveness. J Urol 200(4):786–793
doi: 10.1016/j.juro.2018.05.121
pubmed: 29864437
pmcid: 6786489
Candela L, Kasraeian A, Barret E (2022) Current evidence for focal laser ablation and vascular-targeted photodynamic therapy for localized prostate cancer: review of literature published in the last 2 years. Curr Opin Urol 32(2):192–198
doi: 10.1097/MOU.0000000000000964
pubmed: 35013079
Trachtenberg J, Weersink RA, Davidson SR, Haider MA, Bogaards A, Gertner MR et al (2008) Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses. BJU Int 102(5):556–562
doi: 10.1111/j.1464-410X.2008.07753.x
pubmed: 18494829
Valerio M, Cerantola Y, Eggener SE, Lepor H, Polascik TJ, Villers A et al (2017) New and established technology in focal ablation of the prostate: a systematic review. Eur Urol 71(1):17–34
doi: 10.1016/j.eururo.2016.08.044
pubmed: 27595377
von Hardenberg J, Borkowetz A, Siegel F, Kornienko K, Westhoff N, Jordan TB et al (2021) Potential candidates for focal therapy in prostate cancer in the era of magnetic resonance imaging-targeted biopsy: a large multicenter cohort study. Eur Urol Focus 7(5):1002–1010
doi: 10.1016/j.euf.2020.09.015
Mortezavi A, Krauter J, Gu A, Sonderer J, Bruhin J, Reeve KA et al (2019) Extensive histological sampling following focal therapy of clinically significant prostate cancer with high intensity focused ultrasound. J Urol 202(4):717–724
doi: 10.1097/JU.0000000000000298
pubmed: 31042109
Blazevski A, Scheltema MJ, Yuen B, Masand N, Nguyen TV, Delprado W et al (2020) Oncological and quality-of-life outcomes following focal irreversible electroporation as primary treatment for localised prostate cancer: a biopsy-monitored prospective cohort. Eur Urol Oncol 3(3):283–290
doi: 10.1016/j.euo.2019.04.008
pubmed: 31103721
Guillaumier S, Peters M, Arya M, Afzal N, Charman S, Dudderidge T et al (2018) A multicentre study of 5-year outcomes following focal therapy in treating clinically significant nonmetastatic prostate cancer. Eur Urol 74(4):422–429
doi: 10.1016/j.eururo.2018.06.006
pubmed: 29960750
pmcid: 6156573
Huber PM, Afzal N, Arya M, Boxler S, Dudderidge T, Emberton M et al (2020) Prostate specific antigen criteria to diagnose failure of cancer control following focal therapy of nonmetastatic prostate cancer using high intensity focused ultrasound. J Urol 203(4):734–742
doi: 10.1097/JU.0000000000000747
pubmed: 31928408
Giganti F, Dickinson L, Orczyk C, Haider A, Freeman A, Emberton M, et al. prostate imaging after focal ablation (PI-FAB): a proposal for a scoring system for multiparametric MRI of the prostate after focal therapy. Eur Urol Oncol. 2023.
Baboudjian M, Breda A, Rajwa P, Gallioli A, Gondran-Tellier B, Sanguedolce F et al (2022) Active surveillance for intermediate-risk prostate cancer: a systematic review, meta-analysis, and metaregression. Eur Urol Oncol 5(6):617–627
doi: 10.1016/j.euo.2022.07.004
pubmed: 35934625
Tosoian JJ, Mamawala M, Epstein JI, Landis P, Macura KJ, Simopoulos DN et al (2020) Active surveillance of grade group 1 prostate cancer: long-term outcomes from a large prospective cohort. Eur Urol 77(6):675–682
doi: 10.1016/j.eururo.2019.12.017
pubmed: 31918957
Westhoff N, Ernst R, Kowalewski KF, Derigs F, Neuberger M, Norenberg D et al (2023) Medium-term oncological efficacy and patient-reported outcomes after focal high-intensity focused ultrasound: the FOXPRO trial. Eur Urol Focus 9(2):283–290
doi: 10.1016/j.euf.2022.10.006
pubmed: 36344395
Duwe G, Boehm K, Haack M, Sparwasser P, Brandt MP, Mager R et al (2023) Single-center, prospective phase 2 trial of high-intensity focused ultrasound (HIFU) in patients with unilateral localized prostate cancer: good functional results but oncologically not as safe as expected. World J Urol 41(5):1293–1299
doi: 10.1007/s00345-023-04352-9
pubmed: 36920492
pmcid: 10188406
Noweski A, Roosen A, Lebdai S, Barret E, Emberton M, Benzaghou F et al (2019) Medium-term follow-up of vascular-targeted photodynamic therapy of localized prostate cancer using TOOKAD soluble WST-11 (phase II trials). Eur Urol Focus 5(6):1022–1028
doi: 10.1016/j.euf.2018.04.003
pubmed: 29661587
Marra G, Valerio M, Emberton M, Heidenreich A, Crook JM, Bossi A et al (2019) Salvage local treatments after focal therapy for prostate cancer. Eur Urol Oncol 2(5):526–538
doi: 10.1016/j.euo.2019.03.008
pubmed: 31412013
Pierrard V, Lebdai S, Kleinclauss F, Azzouzi AR, Terrier JE, Fortier E et al (2019) Radical prostatectomy after vascular targeted photodynamic therapy with padeliporfin: feasibility, and early and intermediate results. J Urol 201(2):315–321
doi: 10.1016/j.juro.2018.08.084
pubmed: 30248343
von Hardenberg J, Cash H, Koch D, Borkowetz A, Bruendl J, Leyh-Bannurah SR et al (2021) Triggers and oncologic outcome of salvage radical prostatectomy, salvage radiotherapy and active surveillance after focal therapy of prostate cancer. World J Urol 39(10):3747–3754
doi: 10.1007/s00345-021-03700-x